Legend Biotech (LEGN) Total Liabilities (2019 - 2026)

Legend Biotech (LEGN) has 8 years of Total Liabilities data on file, last reported at $629.0 million in Q1 2026.

• Quarterly Total Liabilities rose 5.2% year-over-year to $629.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $629.0 million (up 5.2% YoY) and the FY2025 annual result came in at $731.6 million, up 16.2% from the prior year.
• Total Liabilities retreated to $629.0 million in Q1 2026, from $731.6 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $731.6 million in Q4 2025 to a low of $499.7 million in Q3 2023.
• A 5-year average of $612.0 million and a median of $611.0 million in 2024 frame the typical range for Total Liabilities.
• The widest YoY moves for Total Liabilities: up 65.95% in 2022, down 99.85% in 2022.
• Tracing LEGN's Total Liabilities over 5 years: stood at $586.7 million in 2022, then increased by 1.8% to $597.2 million in 2023, then grew by 5.42% to $629.6 million in 2024, then increased by 16.2% to $731.6 million in 2025, then retreated by 14.02% to $629.0 million in 2026.
• The last three Total Liabilities figures came in at $629.0 million (Q1 2026), $731.6 million (Q4 2025), and $701.7 million (Q3 2025), per Business Quant data.